Tamil Nadu plans parallel programme with unique user IDs
Will syringe shortage puncture India's Covid vaccine plans?
Lack of clarity on data-sharing persists, public health experts sceptic about the pilot that was run in six Union territories as benchmark for national roll-out
Canada has emerged as the most preferred country for Indian students abroad.
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
The sudden spike in cases of fever in India has claimed over 100 lives in five states, including UP, MP, Bihar, Haryana, and West Bengal. In UP, Firozabad and Mathura alone have reported 72 cases.
Pfizer can show the FDA approval to the Indian regulator and present a case that based on whatever data submitted, the US regulator has granted a full marketing nod, says Sohini Das.
The Centre is looking to procure around 1 billion syringes between September and December to support the COVID-19 vaccination drive.
Gennova has also got permission for phase-2 and 3 clinical trials for its lyophilised mRNA vaccine for injection from the subject expert committee advising the Central Drugs Standards Control Organisation, reports Sohini Das.
Government institutions and pharma industry are examining if a 'cocktail' approach to making a multi-variant Covid-19 vaccine works against multiple strains of the ever-mutating virus, reports Sohini Das.
The health system is trying to ensure that it isn't caught by surprise -- the way it was last time. So, hectic preparations are on.
This year's share of dream and super-dream job offers has spiked. As a result, the overall annual average salary packages have nearly doubled at some of these college campuses.
While Lupin is working on a Remdesivir powder for inhalation, Glenmark has tied up with a Canadian Biotech firm for nitric oxide nasal spray that reduces Sars-CoV-2 viral load and thus transmission.
The US mission to India has invited students to visit https://educationusaindia.usief.org.in/ and also participate in the EducationUSA University Virtual Fairs, to be held on Friday, August 27, for prospective graduate students and Friday, September 3, for prospective undergraduate students.
If things go according to plan, the vaccine would be available in the market by the end of this year.
With Canada, Australia extending restrictions, admission seekers are deferring their studies or looking elsewhere.
Adar Poonawalla said he was hopeful that Covovax, the Novavax vaccine made by SII, will be launched around October this year for adults and for children by the first quarter of next year, depending on DCGI approvals.
India is not keen to 'bow down' to demands related to indemnity against legal liabilities in case any vaccine recipient develops severe adverse reactions post inoculation.
While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
But no extra risk after second dose, shows study led and funded by drug maker, reports Sohini Das.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances